Skip to main content

Table 5 Multivariable logistic regression analysis between serum vitamin D levels and JIA- related outcomes

From: Vitamin D, oral health, and disease characteristics in juvenile idiopathic arthritis: a multicenter cross-sectional study

JIA-related outcomes

Yes/No

N

Serum 25(OH) vit. Das exposure

Model 1

Adjusteda

OR (95% CI)

Disease duration ≥ 4 yearsb

92/65

 ≥ 50 nmol/L

1 (ref.)

 

40/26

 < 50 nmol/L

0.83 (0.43–1.60)

Not oligo persistent JIAc

98/59

 ≥ 50 nmol/L

1 (ref.)

 

48/18

 < 50 nmol/L

1.54 (0.77–3.10)

DMARDs ever usedd

120/37

 ≥ 50 nmol/L

1 (ref.)

 

51/15

 < 50 nmol/L

1.29 (0.58–2.87)

Not in remission off medicatione

138/19

 ≥ 50 nmol/L

1 (ref.)

 

56/10

 < 50 nmol/L

0.81 (0.32–2.07)

Active jointsf

35/122

 ≥ 50 nmol/L

1 (ref.)

 

16/50

 < 50 nmol/L

1.07 (0.51–2.24)

VAS pain > 0 g

99/56

 ≥ 50 nmol/L

1 (ref.)

 

37/26

 < 50 nmol/L

0.64 (0.33–1.24)

  1. The column Yes/No, N shows the number of participants with (Yes) and without (No) the JIA-related outcome within each of the two vitamin D exposure groups ≥ 50 nmol/L and < 50 nmol/L
  2. Vit., vitamin; JIA, juvenile idiopathic arthritis; OR, odds ratio; CI, confidence interval; DMARDs, disease-modifying anti-rheumatic drugs; VAS, Visual Analog Scale; iso-BMI, Body Mass Index adjusted for age and sex, corresponding to adult BMI according to International Obesity Task Force; ILAR, International League of Association for Rheumatology
  3. aModel 1: Adjusted for age, sex, geographical region, iso-BMI, and blood sampling performed in 4 seasons (summer, fall, winter, spring)
  4. bDisease duration was categorized into: < 4 years and ≥ 4 years
  5. cJIA categories defined according to the ILAR classification criteria and categorized into oligoarticular persistent JIA (the mildest form), and all other JIA categories
  6. dDMARDs include both synthetic (methotrexate, hydroxychloroquine, cyclosporine, mycophenolate mofetil) and biologic (etanercept, infliximab, adalimumab, tocilizumab, abatacept, certolizumab, golimumab, rituximab) and categorized into never used, and ever used (= previous, or ongoing medication)
  7. eDisease activity (Wallace et al. 2004/2011), categorized into not in remission off medication, and remission off medication
  8. fActive joints at the study visit = children without active joints, and those with one or more active joints
  9. gSelf-reported disease-related pain measured on a 21-numbered circle VAS scale (0 = no pain, 10 = maximum pain) and categorized into no pain (VAS = 0), and pain (VAS > 0) (5 missing)
Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us